{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:37:09Z","timestamp":1793911029798,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006069","name":"Cancer League of Basel","doi-asserted-by":"publisher","award":["KLbB-6352-02-2025"],"award-info":[{"award-number":["KLbB-6352-02-2025"]}],"id":[{"id":"10.13039\/501100006069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017295","name":"Holcim Foundation for the Promotion of Scientific Further Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008595","name":"Medical Department of the Margarete and Walter Lichtenstein Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009845","name":"Ovarian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.105627","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:01:28Z","timestamp":1790175688000},"page":"105627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["International trends and determinants of homologous recombination deficiency and BRCA testing in ovarian cancer management: a cross-sectional study from the European network of young gynaecologic oncologists"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-6572","authenticated-orcid":false,"given":"Tibor A.","family":"Zwimpfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-8354","authenticated-orcid":false,"given":"Houssein","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-3084","authenticated-orcid":false,"given":"Martina Aida","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-6543","authenticated-orcid":false,"given":"Esra","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Sanchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-413X","authenticated-orcid":false,"given":"Maria","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-3894","authenticated-orcid":false,"given":"Joanna","family":"Kacperczyk-Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-0341","authenticated-orcid":false,"given":"Khayal","family":"Gasimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-0896","authenticated-orcid":false,"given":"Zoia","family":"Razumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-1050","authenticated-orcid":false,"given":"Ilker","family":"Kahramanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Strojna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-445X","authenticated-orcid":false,"given":"C\u00e9line","family":"Montavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-6385","authenticated-orcid":false,"given":"George","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale W.","family":"Garsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0180-0942","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Petousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.105627_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105627_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.105627_bib3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105627_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105627_bib5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105627_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijgc.2026.105627_bib7","series-title":"Ovarian cancer survival rates 2004-2020, updated 08.06","year":"2023"},{"issue":"12","key":"10.1016\/j.ijgc.2026.105627_bib8","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jamaoncol.2021.4252","article-title":"Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer","volume":"7","author":"Melamed","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.105627_bib9","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ijc.34403","article-title":"Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study","volume":"152","author":"Cabasag","year":"2023","journal-title":"Int J Cancer"},{"issue":"15","key":"10.1016\/j.ijgc.2026.105627_bib10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7035","key":"10.1016\/j.ijgc.2026.105627_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105627_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105627_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.105627_bib14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.105627_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.ijgc.2026.105627_bib16","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.105627_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonz\u00e1lez-Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ijgc.2026.105627_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ijgc.2026.105627_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.41648","article-title":"PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: a systematic review and meta-analysis","volume":"8","author":"Petousis","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105627_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7353","key":"10.1016\/j.ijgc.2026.105627_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"7553","key":"10.1016\/j.ijgc.2026.105627_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2026.105627_bib23","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ijgc.2026.105627_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1387281","article-title":"Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group","volume":"14","author":"Stiegeler","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105627_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"21","key":"10.1016\/j.ijgc.2026.105627_bib26","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105627_bib27","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105627_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"9990","key":"10.1016\/j.ijgc.2026.105627_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"10106","key":"10.1016\/j.ijgc.2026.105627_bib30","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105627_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.6004\/jnccn.2022.7257","article-title":"Nationwide trends and determinants of germline BRCA1\/2 testing in patients with breast and ovarian cancer","volume":"21","author":"Lau-Min","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105627_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100029","article-title":"BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway","volume":"35","author":"Birgisd\u00f3ttir","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"15","key":"10.1016\/j.ijgc.2026.105627_bib33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.105627_bib34","article-title":"Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study","volume":"5","author":"Gardner","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.105627_bib35","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/cancers17152541","article-title":"Barriers and breakthroughs in precision oncology: a national registry study of BRCA testing and PARP inhibitor uptake in women from the National Gynae-Oncology Registry (NGOR)","volume":"17","author":"Naidoo","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105627_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/ijgc-2022-003913","article-title":"Systematic mapping review of guidelines for BRCA1\/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer","volume":"33","author":"Hughes","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105627_bib37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/ijgc-2022-003637","article-title":"Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology\/Young Academy of Gynecologic Oncology\/Arbeitsgemeinschaft Gynakologische Onkologie intergroup analysis","volume":"32","author":"Nguyen-Str\u00e4uli","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105627_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35590","article-title":"Global disparities in cancer care: bridging the gap in affordability and access to medications between high and low-income countries","volume":"131","author":"Tfayli","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ijgc.2026.105627_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s43856-022-00097-5","article-title":"Global disparities in access to cancer care","volume":"2","author":"Dos-Santos-Silva","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105627_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/jpm13020284","article-title":"Homologous recombination deficiency in ovarian cancer: from the biological rationale to current diagnostic approaches","volume":"13","author":"Mangogna","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.ijgc.2026.105627_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115169","article-title":"Homologous recombination deficiency in ovarian cancer: global expert consensus on testing and a comparison of companion diagnostics","volume":"215","author":"Quesada","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.105627_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105627_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:12:21Z","timestamp":1793909541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26011588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S1048891X26011588"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105627","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International trends and determinants of homologous recombination deficiency and BRCA testing in ovarian cancer management: a cross-sectional study from the European network of young gynaecologic oncologists","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"105627"}}